Biothera Research Shows Potential For Treating Imprime PGG Biomarker-Negative Cancer Patients
1/16/2014 9:04:39 AM
EAGAN, Minn.--(BUSINESS WIRE)--Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG® in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute’s Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.
Help employers find you! Check out all the jobs and post your resume.
comments powered by